DR. STEVEN BALK
Osteopathic Medicine at Brookline Ave, Boston, MA

8084020, Dec 27, 2011

May 1, 2003

10/513109

Mark A. Exley - Chestnut Hill MA, US
Steven P. Balk - Needham MA, US
Simon C. Yue - Brighton MA, US

Beth Israel Deaconess Medical Center - Boston MA

A61K 45/00, A61K 39/395, A61K 39/00, C07K 14/00, C07K 16/00, C07K 16/28

424 851, 424 852, 4241301, 4241331, 4241411, 4241431, 4241521, 4241561

The invention provides methods for the administration of an anti-CD 1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer.

8138314, Mar 20, 2012

Oct 2, 2006

11/541958

Mark A. Exley - Chestnut Hill MA, US
Samuel B. Wilson - Lexington MA, US
Steven P. Balk - Needham MA, US

Beth Israel Deaconess Medical Center, Inc. - Boston MA
Dana-Farber Cancer Institute - Boston MA
The General Hospital Corporation - Boston MA

C12P 21/08

5303873, 53038822

The invention provides compounds and methods for the ex vivo or in vivo expansion of NK T cells, CD1d-reactive T cells, and JαQ T cells, and the modulation of their activities. These compounds and methods have diagnostic and therapeutic applications.

2002016, Nov 7, 2002

Jun 19, 2001

09/885768

Mark Exley - Chestnut Hill MA, US
Samuel Wilson - Lexington MA, US
Steven Balk - Needham MA, US

A61K039/395, C07K016/28

424/144100, 530/388220

The invention provides compounds and methods for the ex vivo or in vivo expansion of NK T cells, CD1d-reactive T cells, and JQ T cells, and the modulation of their activities. These compounds and methods have diagnostic and therapeutic applications.

2003016, Sep 4, 2003

Jan 19, 2001

09/765815

Steven Balk - Needham MA, US

A61K031/56, C12N009/12

514/169000, 435/194000

The present invention features a novel p21-activated kinase that interacts with steroid hormone receptors, the steroid hormone receptor interacting p21-activated kinase (PAK). In general, the invention provides methods of inhibiting hormone related cancers. More particularly, the present invention relates to inhibiting prostate cancer and breast cancer. The present invention further provides methods of activating the therapeutic effects of steroid hormone receptors, particularly the estrogen receptor. Alternatively, the present invention provides methods of diagnosing steroid hormone receptor-related diseases.

2012016, Jun 28, 2012

Dec 6, 2011

13/312114

Mark A. Exley - Chestnut Hill MA, US
Steven P. Balk - Needham MA, US
Simon C. Yue - Brookline MA, US

Beth Israel Deaconess Medical Center - Boston MA

A61K 39/395, A61P 37/00, A61P 31/04, A61P 33/00, A61P 37/08, A61P 11/06, A61P 29/00, A61P 37/06, A61P 37/04, A61P 15/06, A61P 31/14, A61P 31/16, A61P 31/18, A61P 3/10, A61P 19/02, A61P 25/00, A61P 21/04, A61P 15/00, A61P 31/00, A61P 31/12

4241331, 4241731

The invention provides methods for the administration of an anti-CD1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer.

2012025, Oct 11, 2012

Mar 19, 2012

13/423683

Mark A. Exley - Chestnut Hill MA, US
Samuel B. Wilson - Micanopy FL, US
Steven P. Balk - Needham MA, US

Beth Israel Deaconess Medical Center, Inc - Boston MA
The General Hospital Corporation - Boston MA
Dana Farber Cancer Institute - Boston MA

A61K 39/395, A61P 37/00, A61P 31/12, A61P 31/04, A61P 33/00, A61P 31/00, A61P 37/06, A61P 15/06, A61P 15/04, A61P 37/08, A61P 11/06, A61P 29/00, A61K 39/44, A61K 51/10, A61P 35/00, A61P 3/10, A61K 35/14, C12N 5/0783, C07K 16/28

424 149, 5303891, 4241721, 4241831, 424 9371, 435325, 435375

The invention provides compounds and methods for the ex vivo or in vivo expansion of NK T cells, CD1d-reactive T cells, and JαQ T cells, and the modulation of their activities. These compounds and methods have diagnostic and therapeutic applications.

2014007, Mar 20, 2014

Sep 9, 2013

14/021825

Lydia Lynch - Brookline MA, US
Donal O'Shea - Dublin, IE
Cliona O'Farrelly - Wexford, IE
Steven P. Balk - Needham MA, US

Beth Israel Deaconess Medical Center, Inc. - Boston MA

A61K 39/395, A61K 35/14, A61K 45/06, A61K 31/7032

424450, 514 25, 4241721, 424 9371

The present invention relates to the discovery that increases in invariant NKT cell (iNKT) number and/or activity can reduce the incidence or severity of metabolic disorders such as obesity and diabetes. The invention accordingly features methods, kits, and compositions for the treatment of such metabolic disorders by administration of a composition capable of increasing iNKT activity.